إيماتينيب ميسيلات
| Kind | API |
|---|---|
| Class | Antineoplastic — tyrosine kinase inhibitor (BCR-ABL) |
| Synonyms | Imatinib mesilate, STI-571, CGP 57148B |
| Common uses / forms | Film-coated tablets/capsules 100/400 mg; CML, GIST, Ph+ ALL |
| Properties | BCS Class I; high solubility but pH-dependent (freely soluble in acidic media, falls off above ~pH 6), high permeability; mesylate salt; polymorphic — metastable alpha vs stable beta form |
| Compendia | USP, EP, BP, IP |
| Sourcing origins | India, China |
| Dominant inbound route | Hormuz |
| Indicative price band | $$$ ($100–1000 / kg) |
| Indicative lead time | medium (50–80 days) |
| Notes | Beta polymorph control was patent-sensitive; genotoxic mesylate-ester impurity limits apply; many generic producers post-patent. |
Open the interactive Data Bank (363 substances) · the full table · Supply Resilience Studio
Share: LinkedIn · X · WhatsApp · Telegram · Email
Cite as: AUPAM Experts' Office, Imatinib mesylate — sourcing profile (API) — AUPAM Data Bank, retrieved 2026-08-31, https://aupameo.org/datasets/databank/a-imatinib-mesylate.html